It was observed by several investigators that, although there is a drop in hepatitis B virus (HBV) DNA or HBV DNA polymerase (DNA-p) in the serum of patients treated with adenine arabinoside (Ara-A) or interferon (IFN), the concentration becomes undetectable only in a small percentage of patients, and a sustained seroconversion occurs in only a minority. There are several factors affecting trials of Ara-A and IFN. The characteristics of patients treated vary substantially. Oriental people, who have a high infection rate in early life, do poorly with Ara-A and IFN, whereas northern Europeans exhibit better results.' We need new drugs in which the mechanism of action is different from that of IFN.
In HB virus induced liver disease, cytotoxic T cells are probably responsible for the destruction of liver cells.' Interleukin 2 (IL 2) causes cytotoxic T cells to increase in number and to mature.3 T cells in the peripheral blood from patients in the exacerbation stage of chronic hepatitis produce more IL 2 than in the remission stage.' There is a possibility that exogenous IL 2 may make cytotoxic T cells proliferate, and eliminate infected hepatocytes.
The aim of this study was to determine whether or not IL 2 is effective in Japanese patients chronically infected with HB virus.
Methods

PATI ENTS
Recombinant IL 2 (rIL 2) was provided by Takeda Chemical Industries Ltd (Osaka in Japan). The activity of T cell proliferation by one unit of this rIL 2 was equal to about 500 units of Gillis.' Between June 1985 and March 1986, 11 HBs antigen (Ag) and HBe Ag positive men (Table 1) were treated with rIL 2. Two hundred and fifty to 1000 units were administered iv daily for 60 minutes from seven to a maximum of 28 days. The diagnosis of chronic active hepatitis and chronic persistent hepatitis was established histologically for all patients.
Serum and plasma samples were taken before, during, and after therapy and stored at -20°C. HBs Ag was quantitatively assayed by haemagglutination. HBe Ag and anti-HBe were detected by radioimmunoassay (Dinabbott). Patients were followed for a period of six months by serum titrations of the HBs Ag/Ab and HBe Ag/Ab. DNA polymerase activity specific to HB virus was measured according to a modified method of Kaplan et al'; the 1648 Table 2 shows the results of the serological study Table 1 represents the cases, changes in s-GPT and and the 2-5 AS activity before and after therapy. Two side effects. Three of 11 patients (case nos 3, 5, 10) of 11 patients lost HBs Ag, and gained anti-HBs showed a transient rise in s-GPT during IL 2 therapy. antibody. Two patients lost HBe Ag, one gained antiThere was no significant difference in s-GPT activity HBe antibody. A decrease of DNA-p activity was observed in six of 11 patients. The activity of DNA-p in serum before rIL 2 administration was 745±1338 cpm (mean±standard deviation, n=11), and was reduced to 398±391 cpm after therapy, this was not statistically significant. There were no significant changes in 2-5 AS activity in the patients starting therapy.
The data of T cell subpopulations and natural killer cell activity in peripheral blood before and after rIL 2 therapy are shown in Table 3 . The number of circulating lymphocytes after treatment with rIL 2 was significantly greater than before treatment (p<OO1). CD4 positive cells also showed a significant increase after therapy (p<005). The number of CD8 positive cells and CD16 positive cells, however, was unchanged. Nine of 11 patients showed an increase in natural killer cell activity after rIL 2 therapy, and there was a significant increase in natural killer cell activity in patients treated with rIL 2 (p<0.01).
Histological data in case nos 5, 6, 7, 8, 9, 10 and 11 before and after therapy are shown in Table 4 . The number of intrahepatic lymphocytes decreased markedly. Focal and piecemeal necrosis decreased in all seven cases, and CD8 positive cells decreased significantly in number after therapy (p<005). The display of HLA class I increased in three cases (case nos 5, 9, 11).
Discussion
Recombinant IL 2 given intravenously inhibited DNA-p activity in six of 11 patients. The decrease in DNA-p activity, however, was not pronounced, and there was no significant change during therapy. The antiviral activity of rIL 2 may be weaker than that of IFN and Ara-A. rIL 2 did not increase the activity of 2-5 AS in mononuclear cells, and probably inhibited the replication ofHBV through a different mechanism from alpha and beta IFN, which induces 2-5 AS. There is a possibility that exogenous rIL 2 induces the production of gamma IFN, which cannot induce 2-5 AS the same as alpha and beta IFN."' The associated rise in s-GPT during therapy may indicate an increased rate of lysis of infected hepatocytes, resulting from an enhanced immune response to the virus. The increase in s-GPT is probably not attributable to a direct hepatotoxic effect of IL 2, because there were no changes of liver cells in the post-treated biopsy specimens, and therapeutic doses of rIL 2 have no influence on hepatocytes in experimental animals (personal communication).
We have reported that T cells from patients with chronic hepatitis produced more IL 2 during exacerbation than during remission,4 and have suggested that rIL 2 may induce a proliferation of cytotoxic T cells which in turn destroy liver cells in patients with chronic hepatitis. T cells in the peripheral blood from patients with chronic hepatitis responded to exogenous IL 2, and the uptake of H-thymidine was the same as in normal controls. " We also monitored changes in lymphocyte subpopulations serially during the first 24 hours after administration of IL 2." The ratio of CD4 to CD8 positive cells significantly increased one hour after the start of rIL 2 therapy. This change was transient, however, lasting only four hours after administration of rIL 2, and serum IL 2 concentrations decreased very quickly. In the present study, the number of lymphocytes and CD4 positive cells, which may induce increased production of immunoglobulin, showed an increase after rIL 2 therapy. There are some reports that IL 2 increases the production of humoral antibodies by B cells. Ralph et There is a possibility that IL 2 increases production of HLA class I protein, because IL 2 induces the production of gamma-IFN in lymphocytes. '4 In the present study, HLA class I displays on liver cells increased in three of seven cases. This increase on the infected hepatocyte membrane may enhance lysis by cytotoxic T cells sensitised to HB virus antigen.
The increase in natural killer cell activity might be advantageous in the elimination of HB virus infected hepatocytes. The effects of IL 2 upon the immune system are numerous as have already been described. These effects may create a favourable environment for the elimination of the infected liver cells by immunocytes.
The side effects were a slight and transient headache and a low grade fever. The myalgia, high fever, leucopenia and thrombocytopenia, which accompany IFN therapy, were not observed.
The length of treatment chosen was 28 days, because IFN was administered for 28 days at the beginning of clinical trial. Further studies into this problem are necessary.
These observations indicate that in HBe Ag positive patients rIL 2 acts as an immunomodulating agent enhancing host immune activity and may be more effective than IFN and Ara-A in oriental people with chronic HB virus infection who show almost no response to antiviral therapy. A randomised, controlled study is in progress to evaluate the effectiveness of this well tolerated regime in producing longterm inhibition of HB virus replication and amelioration of the associated inflammatory liver disease.
